Sciwind Biosciences Announces Ecnoglutide Injection Approved by China’s National Medical Products Administration (NMPA) for Chronic Weight Management

2026-03-06 - 07:35

HANGZHOU, China, March 6, 2026 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd. (“Sciwind”), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China’s National Medical Products Administration (NMPA) has approved Ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. Ecnoglutide injection is the